Dr. Rathmell is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1211 Medical Center Dr
Nashville, TN 37232Phone+1 615-322-5000Fax+1 615-936-0320- Is this information wrong?
Summary
- Dr. W. Kimryn Rathmell is an oncologist in Nashville, TN and is affiliated with Vanderbilt University Medical Center, where she currently serves as the Chair of Medicine. She received her medical degree from Stanford University School of Medicine and has been in practice 19 years. She specializes in genitourinary oncology and genetic oncology and is experienced in hematologic oncology, urologic oncology, internal medicine, medical oncology, and hereditary risk associated kidney neoplasms.
Education & Training
- University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2000 - 2004
- University of Pennsylvania Health SystemResidency, Internal Medicine, 1999 - 2002
- University of ChicagoInternship, Internal Medicine, 1998 - 1999
- Stanford University School of MedicineClass of 1998
- Stanford UniversityPh.D., Biophysics, 1993 - 1996
- University of Northern IowaBS, Biology, 1987 - 1991
- University of Northern IowaBA, Chemistry, 1987 - 1991
Certifications & Licensure
- TN State Medical License 2015 - 2025
- KY State Medical License 2021 - 2024
- IA State Medical License 2021 - 2023
- WI State Medical License 2021 - 2023
- MS State Medical License 2021 - 2022
- AL State Medical License 2020 - 2022
- NC State Medical License 2003 - 2016
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Awards, Honors, & Recognition
- Alpha Omega Alpha 2013
- Alpha Omega Alpha (AOA) induction 2014
- Ruth and Philip Hettelman Award for Scholarly Achievement 2012
- Join now to see all
Clinical Trials
- Sorafenib in Treating Patients Undergoing Surgery for Stage II, Stage III, or Stage IV Kidney Cancer Start of enrollment: 2006 Nov 01
Publications & Presentations
PubMed
- 14 citationsElevated transferrin receptor impairs T cell metabolism and function in systemic lupus erythematosus.Kelsey Voss, Allison E Sewell, Evan S Krystofiak, Katherine N Gibson-Corley, Arissa C Young, Jacob H Basham, Ayaka Sugiura, Emily N Arner, William N Beavers, Dillon E ...> ;Science Immunology. 2023 Jan 13
- 4 citationsEngineering functional 3-dimensional patient-derived endocrine organoids for broad multiplatform applications.Naira Baregamian, Konjeti R Sekhar, Evan S Krystofiak, Maria Vinogradova, Giju Thomas, Emmanuel Mannoh, Carmen C Solórzano, Colleen M Kiernan, Anita Mahadevan-Jansen, ...> ;Surgery. 2023 Jan 1
- 8 citationsA global view of the aspiring physician-scientist.Christopher S Williams, W Kimryn Rathmell, John M Carethers, Diane M Harper, Y M Dennis Lo, Peter J Ratcliffe, Mone Zaidi> ;Elife. 2022 Sep 13
- Join now to see all
Journal Articles
- Publisher Correction: Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination with Bevacizumab Versus Sunitinib in Renal Cell Ca...Michael B Atkins, Mario Sznol, Robert J Motzer, Richard W Joseph, Thomas Hutson, John Hainsworth, W Kimryn Rathmell, Brian I Rini, David F McDermott, Toni K Choueiri, ..., Nature
- Epigenetic Modifiers: Activities in Renal Cell CarcinomaW. Kimryn Rathmell, MD, Nature
- VHL Substrate Transcription Factor ZHX2 as an Oncogenic Driver in Clear Cell Renal Cell CarcinomaEric Jonasch, Xian Chen, William Y Kim, W Kimryn Rathmell, Science Magazine
- Join now to see all
Books/Book Chapters
Lectures
- Renal Cell Carcinoma.Nashville, TN - 1/1/2016
- Translational Research at the Bioinformatic Edge.Schloss Dagstuhl, Wadern, Germany - 1/1/2016
- Renal Medullary CarcinomaNashville, TN - 1/1/2016
- Join now to see all
Other
- Tumor Genomics ProgramRathmell, WK
http://university.asco.org/tumor-genomics-program
ASCO University. - 1/1/2014 - Comment on autophagy related to VHL gene as a strategy to develop cancer treatmentsRathmell, WK, NPR Morning Edition.
1/1/2008 - mTOR: An Emerging Pathway in CancerRathmell, WK. and Shaw R., Novartis Internal Training Module.
1/1/2008 - Join now to see all
Authored Content
- ASCO Afterthoughts? Many Missions of the Annual MeetingJune 2019
- ASCO Afterthoughts? Many Missions of the Annual MeetingJune 2019
Grant Support
- Genetic Events In The Development Of Renal Cell CarcinomaNational Cancer Institute2007–2011
- Functional And Tissue Specific Effects Of VHL MutationsNational Cancer Institute2003–2007
- Dendritic Cell Vaccine (Mb-002) To Patients With Metastatic Renal Cell CarcinomaNational Center For Research Resources2006
- Calgb 90206: Interferon Alfa-2b Or 2B PLUS Bevacizumab In Renal CarcinomaNational Center For Research Resources2006
- Functional And Tissue Specific Effects Of VHL MutationsNational Cancer Institute2003
Professional Memberships
- Member
- Member
Hospital Affiliations
- Vanderbilt University Medical CenterNashville, Tennessee
External Links
- VUMC Heme Onchttps://medicine.mc.vanderbilt.edu/welcome-division-hematologyoncology
- VICChttp://www.vicc.org/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: